Drug Type Synthetic peptide vaccine, Prophylactic vaccine |
Synonyms Asudemotide + [1] |
Target |
Mechanism DEPDC1 inhibitors(DEP domain containing 1 inhibitors), KIF20B inhibitors(kinesin family member 20B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Esophageal Carcinoma | Phase 3 | - | - | |
Bladder Cancer | Phase 2 | - | - | |
Bladder Cancer | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | - | - |
Phase 2 | Metastatic urothelial carcinoma Maintenance | 81 | sqtbmfsvsw(ymjkzrsgtg) = hmwobmxqap pjcxitrket (rwxoymrcsq ) View more | - | 02 Mar 2021 | ||
(Observation group) | (ujodknocnj) = tlqighasii drmwfudjfc (ufhkfoserf ) View more | ||||||
Phase 1 | 15 | tqjhddwscq(ajxxrzbpvb) = yenalmrvjc lxbkknwocg (qrnexwlgjx ) View more | - | 20 Oct 2018 |